about
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy.A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular GenomesOutcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions.Gene Therapy in a Patient with Sickle Cell Disease.Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1.Thyroid hormone inhibits the human prolactin gene promoter by interfering with activating protein-1 and estrogen stimulations.Abnormal transduction mechanisms in pituitary adenomas.Transcription factor AP1 is involved in basal and okadaic acid-stimulated activity of the human PRL promoter.Protein kinase C regulation of prolactin gene expression in lactotroph cells: involvement in dopamine inhibition.Regulatory CD8+ T cells control neonatal tolerance to a Th2-mediated autoimmunity.Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients.Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.[Membrane receptors and coupling proteins in adenohypophyseal cells]Neonatal induction and maintenance of tolerance to Th2-induced immune manifestations in ratsNeonatal induction of tolerance to Th2-mediated autoimmunity in ratsAlteration of Gα Subunits mRNA Levels in Bromocriptine Resistant Prolactinomas[Etiopathogenesis of pituitary tumors]Normal IgG protects against acute graft-versus-host disease by targeting CD4(+)CD134(+) donor alloreactive T cells
P50
Q24618997-1CB6D285-0414-4EC3-BE76-82BFE87BC777Q28290118-CDACCC2A-0F71-457E-B3BE-393B73BF7FE6Q33640197-C8445C61-E7B5-49A3-BBDC-16521EDE049DQ34763502-77DDFE23-1312-4045-AE33-F5F27CA5C10FQ35011497-0BBC9F87-0098-4A87-8D17-B2DBEAE83733Q36323403-CE652664-E8C5-427B-AA4A-ED2531FF9276Q37089728-79E7DEE3-BE08-40C1-B48D-42C2073ECE80Q38874946-2E78D56C-85AB-41D3-961B-8A3589126F8EQ40313066-25EF72A1-5B2B-4BBE-B03D-5D0A8117AF1AQ41079369-1728D8CE-AA9E-4CD7-BBA8-30969B073737Q41108192-175CF5BB-5051-470D-8F48-89ACDA0858C6Q41485479-FFBA0FAB-109F-49D3-BF62-4613FF790C9AQ42460354-DD969868-5316-4D81-9DC3-353C883BC123Q42482751-13DDA687-553A-4F3F-92F0-237E49B80CD8Q44320778-B4A83D2F-5256-4DCA-BF3D-73B246795ABAQ45609885-F83B389F-0FC9-4A10-A92F-08CEE3D40913Q54195830-1B61F0DF-F4D7-48FD-BA5F-B90FA91B6153Q54253755-C2F27DB3-2903-4EBF-852F-9ADC598C680EQ61054172-46644317-64EF-4257-A942-0C49D65C964AQ61054173-6A71EED5-EDE4-4EA5-ACC6-0687A6C3B255Q62741573-B270826C-8BF7-4CAE-A643-FE7400322B65Q62741589-B608038F-4F4D-4B3B-94F3-D314B233DBAFQ74460593-EAF66F77-1391-4D48-BBAA-120B39895F8A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laure Caccavelli
@ast
Laure Caccavelli
@en
Laure Caccavelli
@es
Laure Caccavelli
@nl
Laure Caccavelli
@sl
type
label
Laure Caccavelli
@ast
Laure Caccavelli
@en
Laure Caccavelli
@es
Laure Caccavelli
@nl
Laure Caccavelli
@sl
prefLabel
Laure Caccavelli
@ast
Laure Caccavelli
@en
Laure Caccavelli
@es
Laure Caccavelli
@nl
Laure Caccavelli
@sl
P1053
H-8880-2017
P106
P21
P31
P3829
P496
0000-0001-6324-2304